CA
NZ
UK
AU
IND
US
Few clinical-stage micro-caps illustrate the tightrope of small-company biotech quite like Propanc Biopharma, Inc. (NASDAQ:PPCB). Trading around the $1 mark and carrying a marketCapitalizationof only a few million dollars, the cancer-focused developer sits close to the sameNasdaqthreshold that forced a dramatic corporate reset earlier …
Some tickers go quiet for a simple reason: the company behind them has effectively ceased to operate. That is the story of Pure Global Cannabis Inc. (OTC:PRCNF), a Canadian cannabis producer that collapsed into creditor protection more than six years ago.
Petros Pharmaceuticals, Inc (OTC:PTPI) is the kind of sub-penny stock where sharp percentage swings say more about a thin share count and low liquidity than about company fundamentals. Once a Nasdaq-listed men's-health specialist, Petros wasDelistedin 2025, completed a 1-for-25 reverse stock split, and now …
● Provectus is a clinical-stage biotechnology company founded in 2002 and built around its proprietary small molecule rose bengal sodium.
The Praxsyn Corporation (OTC:PXYN) once built aBusinessaround compounded, non-narcotic pain creams aimed at California's workers'-compensation system. Today its stock trades at a fraction of a cent with a market value in the hundreds of dollars and no confirmed catalyst, a familiar profile among dormant …
Once known for early-stage antibiotics and probiotics work, Oragenics Inc (NYSE American:OGEN) has reinvented itself as a neuroscience-focused developer built around intranasal drug delivery for brain injury. The company, listed on NYSE American under the ticker OGEN, is a sub-dollar micro-cap advancing a mid-stage …
● A single-session dip of around 5% barely registers as news for a development-stage biotech, and in the case of OKYO Pharma the recent slide arrives against an otherwise constructive backdrop.
● Oncolytics Biotech is a Calgary-based, Nasdaq-listed clinical-stage biotechnology company developing pelareorep, an intravenously administered formulation of a reovirus designed to stimulate an anti-tumor immune response.
● The modest one-day rise does not map to a single confirmed same-session catalyst; at fractions of a cent, OTLC moves are heavily influenced by thin liquidity.
OncoVista Innovative Therapies, Inc. (OTC:OVIT) is one of those names that lingers on quote screens long after the working company behind it has gone quiet. Once a San Antonio-based clinical-stage pharmaceutical developer with ambitions in oncology, OncoVista today trades as a sub-penny shell, priced …
Please wait processing your request...